T1	Participants 119 158	Japanese familial hypercholesterolemia.
T2	Participants 174 208	familial hypercholesterolemia (FH)
T3	Participants 609 684	24 initial patients, 17 heterozygous FH patients (age: 54.1 years; 5 males)
T4	Participants 862 898	Fifteen patients completed the trial
